---
title: "Cue Biopharma Appoints Dominic Borie As CMO"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292491895.md"
description: "Cue Biopharma appointed Dominic Borie as Chief Medical Officer and Head of R&D, effective immediately. Borie reports to CEO Shao-Lee Lin and previously served at Kyverna Therapeutics, Horizon Therapeutics, Genentech, Amgen, and Roche. The company remains on track to report Phase 2 CUE-221 data by Q3 2026 and initiate a Phase 1 trial of CUE-401 by Q4 2026. Pre-market trading shows Cue Biopharma down 1% at $8.40."
datetime: "2026-07-13T12:55:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292491895.md)
  - [en](https://longbridge.com/en/news/292491895.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292491895.md)
---

# Cue Biopharma Appoints Dominic Borie As CMO

Add  as your preferred news source on Google

 Add Now

Cue Biopharma, Inc. (CUE), on Monday, announced that it appointed Dominic Borie as Chief Medical Officer and Head of Research & Development, effective immediately.

Dominic Borie will report to President and Chief Executive Officer Shao-Lee Lin.

Borie most recently served as Strategic Advisor to the CEO and Board of Kyverna Therapeutics, Inc. (KYTX) and previously held senior leadership roles at Horizon Therapeutics, Genentech, Amgen and Roche.

The company said it remains on track to report Phase 2 CUE-221 data by the end of the third quarter of 2026 and initiate a Phase 1 trial of CUE-401 by the end of the fourth quarter.

In the pre-market trading, Cue Biopharma is 1% lesser at $8.40 on the Nasdaq.

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [CUE.US](https://longbridge.com/en/quote/CUE.US.md)
- [KYTX.US](https://longbridge.com/en/quote/KYTX.US.md)

## Related News & Research

- [Cue Biopharma (NASDAQ:CUE) Posts Quarterly Earnings Results, Misses Estimates By $22.45 EPS](https://longbridge.com/en/news/295985422.md)
- [Cue Biopharma (CUE) Expected to Announce Earnings on Tuesday](https://longbridge.com/en/news/295516016.md)
- [Cue Biopharma Chief Executive Officer Sold Shares Worth Over $1.6M](https://longbridge.com/en/news/295986047.md)
- [Cue Biopharma GAAP EPS of -$24.14 misses by $22.23, revenue of $7.88M beats by $5.78M](https://longbridge.com/en/news/296072164.md)
- [BrainStorm Cell Therapeutics GAAP EPS of -$0.35](https://longbridge.com/en/news/296069988.md)